Observation of the Effect of Xindilizumab Combined with DPF Regimen in the Treatment of Stage Ⅱ/Ⅲ Esophageal Squamous Cell Carcinoma
Objective To explore the therapeutic effect of Xindilimab combined with DPF regimen in the treatment of stage Ⅱ/Ⅲ esophageal squamous cell carcinoma.Methods According to the random number table method,96 patients with stage Ⅱ/Ⅲ esophageal squamous cell carcinoma were divided into the control group(n=48)and the observation group(n=48).The control group was treated with the DPF regimen,while the observation group was treated with a combination of Xindilizumab on the basis of the control group.Both groups were continuously treated for 4 cycles and followed up until March 2023.The clini-cal efficacy,serum tumor markers,immune function,adeverse reactions,and survival were compared between the 2 groups.Results The clinical remission rate in the observation group was higher than that in the control group(P＜0.05).After4 cycles of treat-ment,the levels of serum tumor markers and immune function indicators in both groups improved compared to before treatment,and the observation group showed better improvement in serum tumor marker levels and immune function indicators than the con-trol group(P＜0.05).There was no statistical significant difference in the incidence of toxic side effects such as gastrointestinal reactions,liver dysfunction,bone marrow suppression,thyroid dysfunction,proteinuria,and neutropenia between the 2 treatment groups(P＞0.05).Follow up until March 2023,the average survival time of the observation group was higher than that of the con-trol group(P＜0.05).Conclusion The combination of Xindilizumab and DPF regimen can improve the therapeutic effect of stage Ⅱ/Ⅲ esophageal squamous cell carcinoma patients,reduce serum tumor marker levels,improve patient immune function,and prolong patient survival time without significantly increasing adverse reactions.
NETL
NSTL
万方数据
